184 related articles for article (PubMed ID: 25769882)
1. Re-expression of LKB1 in LKB1-mutant EKVX cells leads to resistance to paclitaxel through the up-regulation of MDR1 expression.
Mao K; Liu F; Liu X; Khuri FR; Marcus AI; Li M; Zhou W
Lung Cancer; 2015 May; 88(2):131-8. PubMed ID: 25769882
[TBL] [Abstract][Full Text] [Related]
2. Modulation of MDR1 and MRP3 gene expression in lung cancer cells after paclitaxel and carboplatin exposure.
Melguizo C; Prados J; Luque R; Ortiz R; Caba O; Alvarez PJ; Gonzalez B; Aranega A
Int J Mol Sci; 2012 Dec; 13(12):16624-35. PubMed ID: 23443122
[TBL] [Abstract][Full Text] [Related]
3. NEAT1 mediates paclitaxel-resistance of non-small cell of lung cancer through activation of Akt/mTOR signalling pathway.
Li B; Gu W; Zhu X
J Drug Target; 2019 Dec; 27(10):1061-1067. PubMed ID: 30782035
[TBL] [Abstract][Full Text] [Related]
4. The tumor suppressor gene TUSC2 (FUS1) sensitizes NSCLC to the AKT inhibitor MK2206 in LKB1-dependent manner.
Meng J; Majidi M; Fang B; Ji L; Bekele BN; Minna JD; Roth JA
PLoS One; 2013; 8(10):e77067. PubMed ID: 24146957
[TBL] [Abstract][Full Text] [Related]
5. Sulforaphane metabolites reduce resistance to paclitaxel via microtubule disruption.
Wang Y; Zhou Y; Zheng Z; Li J; Yan Y; Wu W
Cell Death Dis; 2018 Nov; 9(11):1134. PubMed ID: 30429459
[TBL] [Abstract][Full Text] [Related]
6. Metformin and tenovin-6 synergistically induces apoptosis through LKB1-independent SIRT1 down-regulation in non-small cell lung cancer cells.
Lee BB; Kim Y; Kim D; Cho EY; Han J; Kim HK; Shim YM; Kim DH
J Cell Mol Med; 2019 Apr; 23(4):2872-2889. PubMed ID: 30710424
[TBL] [Abstract][Full Text] [Related]
7. FNDC5 promotes paclitaxel sensitivity of non-small cell lung cancers via inhibiting MDR1.
Fan GH; Zhu TY; Huang J
Cell Signal; 2020 Aug; 72():109665. PubMed ID: 32353410
[TBL] [Abstract][Full Text] [Related]
8. Calpain-2 Enhances Non-Small Cell Lung Cancer Progression and Chemoresistance to Paclitaxel via EGFR-pAKT Pathway.
Xu F; Gu J; Lu C; Mao W; Wang L; Zhu Q; Liu Z; Chu Y; Liu R; Ge D
Int J Biol Sci; 2019; 15(1):127-137. PubMed ID: 30662353
[TBL] [Abstract][Full Text] [Related]
9. siRNA silencing EZH2 reverses cisplatin-resistance of human non-small cell lung and gastric cancer cells.
Zhou W; Wang J; Man WY; Zhang QW; Xu WG
Asian Pac J Cancer Prev; 2015; 16(6):2425-30. PubMed ID: 25824776
[TBL] [Abstract][Full Text] [Related]
10. Drug resistance to paclitaxel is not only associated with ABCB1 mRNA expression but also with drug accumulation in intracellular compartments in human lung cancer cell lines.
Shimomura M; Yaoi T; Itoh K; Kato D; Terauchi K; Shimada J; Fushiki S
Int J Oncol; 2012 Apr; 40(4):995-1004. PubMed ID: 22179563
[TBL] [Abstract][Full Text] [Related]
11. LKB1 gene inactivation does not sensitize non-small cell lung cancer cells to mTOR inhibitors in vitro.
Xiao P; Sun LL; Wang J; Han RL; Ma Q; Zhong DS
Acta Pharmacol Sin; 2015 Sep; 36(9):1107-12. PubMed ID: 26027660
[TBL] [Abstract][Full Text] [Related]
12. Targeting glucosylceramide synthase induction of cell surface globotriaosylceramide (Gb3) in acquired cisplatin-resistance of lung cancer and malignant pleural mesothelioma cells.
Tyler A; Johansson A; Karlsson T; Gudey SK; Brännström T; Grankvist K; Behnam-Motlagh P
Exp Cell Res; 2015 Aug; 336(1):23-32. PubMed ID: 26004871
[TBL] [Abstract][Full Text] [Related]
13. The Effect of LKB1 Activity on the Sensitivity to PI3K/mTOR Inhibition in Non-Small Cell Lung Cancer.
Shukuya T; Yamada T; Koenig MJ; Xu J; Okimoto T; Li F; Amann JM; Carbone DP
J Thorac Oncol; 2019 Jun; 14(6):1061-1076. PubMed ID: 30825612
[TBL] [Abstract][Full Text] [Related]
14. Phosphatidylinositol ether lipid analogues induce AMP-activated protein kinase-dependent death in LKB1-mutant non small cell lung cancer cells.
Memmott RM; Gills JJ; Hollingshead M; Powers MC; Chen Z; Kemp B; Kozikowski A; Dennis PA
Cancer Res; 2008 Jan; 68(2):580-8. PubMed ID: 18199555
[TBL] [Abstract][Full Text] [Related]
15. CHD1L contributes to cisplatin resistance by upregulating the ABCB1-NF-κB axis in human non-small-cell lung cancer.
Li Y; He LR; Gao Y; Zhou NN; Liu Y; Zhou XK; Liu JF; Guan XY; Ma NF; Xie D
Cell Death Dis; 2019 Feb; 10(2):99. PubMed ID: 30718500
[TBL] [Abstract][Full Text] [Related]
16. The Novel Triazolonaphthalimide Derivative LSS-11 Synergizes the Anti-Proliferative Effect of Paclitaxel via STAT3-Dependent MDR1 and MRP1 Downregulation in Chemoresistant Lung Cancer Cells.
Ji L; Liu X; Zhang S; Tang S; Yang S; Li S; Qi X; Yu S; Lu L; Meng X; Liu Z
Molecules; 2017 Oct; 22(11):. PubMed ID: 29072615
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells.
Duan Z; Brakora KA; Seiden MV
Mol Cancer Ther; 2004 Jul; 3(7):833-8. PubMed ID: 15252144
[TBL] [Abstract][Full Text] [Related]
18. Mutant LKB1 Confers Enhanced Radiosensitization in Combination with Trametinib in KRAS-Mutant Non-Small Cell Lung Cancer.
Wang Y; Li N; Jiang W; Deng W; Ye R; Xu C; Qiao Y; Sharma A; Zhang M; Hung MC; Lin SH
Clin Cancer Res; 2018 Nov; 24(22):5744-5756. PubMed ID: 30068711
[No Abstract] [Full Text] [Related]
19. Molecular changes to HeLa cells on continuous exposure to cisplatin or paclitaxel.
Takara K; Obata Y; Yoshikawa E; Kitada N; Sakaeda T; Ohnishi N; Yokoyama T
Cancer Chemother Pharmacol; 2006 Dec; 58(6):785-93. PubMed ID: 16534613
[TBL] [Abstract][Full Text] [Related]
20. Variable apoptotic response of NSCLC cells to inhibition of the MEK/ERK pathway by small molecules or dominant negative mutants.
Brognard J; Dennis PA
Cell Death Differ; 2002 Sep; 9(9):893-904. PubMed ID: 12181740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
